Skip to main content

Advertisement

Table 2 Summary of health state cost and utility inputs

From: Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Health state Cost (2012/13 £) Utility Source
Mean (SE) Mean (SE)
Fibrosis stages
 F0 177.47 (35.01) 0.77 (0.015) [21]
 F1 177.47 (35.01) 0.77 (0.015)
 F2 922.08 (97.82) 0.66 (0.031)
 F3 922.08 (97.82) 0.66 (0.031)
 F4 (compensated cirrhosis) 1463.50 (297.45) 0.55 (0.054)
SVR
 SVR from F0 to F1 333.08 (62.05) 0.82 (0.043) [21]
 SVR from F2 to F3 922.08 (97.74) 0.72 (0.048)
 SVR from F4 (compensated cirrhosis) 1463.50 (288.07) 0.72 (0.048)a
ESLD
 Decompensated cirrhosis 11,728.61 (1954.09) 0.45 (0.031) [21]
 HCC 10,451.58 (2456.09) 0.45 (0.031)
 Liver transplant (transplant cost) 35,147.26 (3709.93) NA
 Liver transplant (cost of care: initial year) 12,163.29 (3133.55) 0.45 (0.031)
 Liver transplant (subsequent years) 1781.15 (456.57) 0.67 (0.066)
  1. HCC hepatocellular carcinoma, NA not applicable, SE standard error, SVR sustained virologic response, ESLD end stage liver disease
  2. aAssumption, based on SVR from F2 to F3